LY01005
As of the edition of 20 October 2026, LY01005 is a drug known only by a code name: in active development; acts on GNRHR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2020
- Kind
- Code name only
- Registered trials
- 5, 0 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | P30968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Luye Pharma | Lead sponsor of trials | 2017 to now |